Denmark’s Genmab A/S is in advanced talks to acquire Dutch biopharmaceutical company Merus NV, specializing in head and neck cancer treatments. Merus, with a market cap of $5.1 billion, has garnered interest from multiple pharmaceutical giants and may finalize a deal soon. If successful, this acquisition would be Genmab’s largest to date.

Read more at Nasdaq: Genmab In Advanced Talks To Acquire Merus : Report